Compositions and methods for treating gonadotrophin related illnesses
AssigneeAllergan Sales, Inc.
InventorStephen Donovan
Life of this patent
Estimating the term…
Abstract
The present invention relates to an agent comprising a neurotoxin, methods for making the agents and methods for treating endocrine disorders, for example gonadotrophin related illnesses. Preferably, the agent comprises at least a portion of a botulinum toxin.
Claims25
An agent comprising:
- a light chain component comprising a light chain or a fragment thereof of a botulimum toxin, a butyricum toxin, a tetani toxin or variants thereof,
- a translocation component comprising a heavy chain or a modified heavy chain of a botulimum toxin, a butyricum toxin, a tetani toxin or variants thereof, and a targeting component which selectively binds to a GnRH receptor.
A method for treating a gonadotrophin related illness in a mammal, said method comprises the step of administering to the mammal a therapeutically effective amount of an agent, the agent comprises:
- a light chain component comprising a light chain, or a fragment thereof, of a botulimum toxin, a butyricum toxin, a tetani toxin or variants thereof,
- a translocation component comprising a heavy chain, or a modified heavy chain, of a botulimum toxin, a butyricum toxin, a tetani toxin or variants thereof and
- a targeting component, wherein the targeting component selectively binds to a GnRH receptor.
A method for treating precocious puberty in a human, said method comprises the step of administering to the mammal a therapeutically effective amount of an agent, the agent comprises:
- a light chain component comprising a light chain or a fragment thereof of a botulimum toxin, a butyricum toxin, a tetani toxin or variants thereof,
- a translocation component comprising a heavy chain or a modified heavy chain of a botulimum toxin, a butyricum toxin, a tetani toxin or variants thereof and
- a targeting component, wherein the targeting component selectively binds to a GnRH receptor.
A method for treating endometriosis in a human, said method comprises:
- a light chain component comprising a light chain, or a fragment thereof, of a botulimum toxin, a butyricum toxin, a tetani toxin or variants thereof,
- a translocation component comprising a heavy chain, or a modified heavy chain, of a botulimum toxin, a butyricum toxin, a tetani toxin or variants thereof and
- a targeting component, wherein the targeting component selectively binds to a GnRH receptor.
Dependencies are inferred from the claim text.